$DYNS News
Last published 2y ago
- 2y agoALCEBYNCLINPNST+4Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition CompaniesGlobeNewswireNEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices of these companies,
- 2y agoALCEATAKBTMCLIN+4Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition CompaniesGlobeNewswireNEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices of these companies,
- 3y agoSNTIDYNSEdelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Senti Biosciences, Incorporated (NASDAQ: SNTI) Shareholders Who Held Dynamics Special Purpose Corp. (NASDAQ: DYNS) Shares Prior to the MergerGlobeNewswireNEWTOWN, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud and breach of fiduciary duty claims on behalf of shareholders of Dynamics Special Purpose Corp.
- 4y agoDYNSSenti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene CircuitsGlobeNewswire- Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti Bio will be listed on the Nasdaq Global Market under t
- 4y agoDYNSSenti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the
- 4y agoDYNSILMNMRNARHHBY+2Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene TherapiesGlobeNewswire- Business combination with Dynamics Special Purpose Corp. (NASDAQ:DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity ("PIPE") financi
- 5y agoDYNSDynamics Special Purpose Corp. Announces Closing of $230 Million Initial Public Offering Including Full Exercise of Underwriters' Over-Allotment OptionBusiness WireDynamics Special Purpose Corp. (the "Company") announced today the closing of its initial public offering of 23,000,000 shares of Class A common stock, which included the full exercise of the underwriters' over-allotment option of 3,000,000 shares of Cl
- 5y agoDYNSDynamics Special Purpose Corp. Announces Pricing of $200 Million Initial Public OfferingBusiness WireDynamics Special Purpose Corp. (the "Company") announced today that it priced its initial public offering of 20,000,000 shares of Class A common stock at $10.00 per share. The shares of Class A common stock are expected to be listed on The Nasdaq Capita